Clascoterone is a prescription cream that treats hormonal acne by blocking androgen signals inside the skin. Hormonal acne means breakouts driven by androgens, hormones that increase oil and inflammation. The cream is sold as Winlevi 1% for acne vulgaris in people 12 and older. Sun Pharma reports that regulators approved it in August 2020 as a first-in-class topical androgen-receptor inhibitor the FDA approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does it target hormonal breakouts?
- How do you use it correctly?
- How well does it work?
- What are the side effects and limits?
How does it target hormonal breakouts?
Clascoterone competes with androgens, especially DHT, for androgen receptors in oil glands and hair follicles. DHT is dihydrotestosterone, a potent androgen that stimulates sebum.
Sebum is skin oil that can clog pores and feed breakouts. By occupying those receptors, the drug limits sebum production and local inflammation at the application site. The effect stays mainly in the skin because the drug breaks down quickly to an inactive form.
How do you use it correctly?
Treatment is prescription-only for ages 12 and older. The National Library of Medicine label directs a thin, uniform layer to cleansed, dry affected skin twice daily, morning and evening the DailyMed drug label.
A typical application is about 1 gram. Avoid the eyes, mouth, and mucous membranes.
- Wash and pat skin fully dry before applying
- Apply only to affected areas, not as a spot treatment
- Skip other irritating topicals unless a clinician approves
- Reduce frequency or pause if burning, peeling, or redness develops
How well does it work?
The strongest evidence comes from two identical multicenter trials, NCT02608450 and NCT02608476, in 1,440 patients with facial acne. Patients received clascoterone or an inactive vehicle cream under double-blind conditions.
Clascoterone produced higher treatment success and larger reductions in both inflammatory and noninflammatory lesions than vehicle, according to the JAMA Dermatology report the Phase 3 trial report. Inflammatory lesions are red, tender bumps, while noninflammatory lesions are blackheads and whiteheads.
What are the side effects and limits?
Adverse events in the trials were uncommon, mostly mild, and similar to vehicle. The most common local reaction was trace or mild redness, called erythema. Labeling also lists itching, burning, peeling, dryness or scaling, swelling, and stinging.
Because the drug has limited systemic exposure, the trials reported no systemic antiandrogen effects such as menstrual irregularities the JAMA review. Twice-daily use for two weeks caused temporary HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents, with recovery by four-week follow-up. The HPA axis controls cortisol, a stress hormone, and younger patients may face higher risk for systemic effects. Stop use and call the prescriber for persistent irritation, swelling, very dry or cracked skin, or signs of hormone disruption.